Hoth Therapeutics Shares Recover; Company Has No Plans for Offering

Dow Jones

Jan 09, 2025

By Josh Beckerman

Shares of Hoth Therapeutics rebounded after the company said it has no plans for a public or private offering at this time.

Hoth stock was recently up 4.6%, at $2.38, in midday trading Wednesday, after falling sharply to a low point of $1.17 from a 52-week high Tuesday. The stock closed up 178%, to $2.28, on Tuesday, after the company reported favorable interim results from a clinical trial.

The company said it was responding to market rumors and shareholder inquiries. It also said enrollment in a clinical trial of HT-001, its lead drug candidate, is proceeding as planned, with all trial sites now active and enrolling participants. HT-001 is designed to treat rash and skin disorders associated with cancer therapy.

"Hoth's financial position remains robust, with a strong balance sheet that includes over $10 million in cash and no debt," the company said.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

January 08, 2025 14:44 ET (19:44 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2502029427"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2502029427\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2502029427?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-09 03:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502029427","market":"fut","top_or_hot":-1,"title":"Hoth Therapeutics Shares Recover; Company Has No Plans for Offering","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> rebounded after the company said it has no plans for a public or private offering at this time. \n</p>\n<p>\n  Hoth stock was recently up 4.6%, at $2.38, in midday trading Wednesday, after falling sharply to a low point of $1.17 from a 52-week high Tuesday. The stock closed up 178%, to $2.28, on Tuesday, after the company reported favorable interim results from a clinical trial. \n</p>\n<p>\n  The company said it was responding to market rumors and shareholder inquiries. It also said enrollment in a clinical trial of HT-001, its lead drug candidate, is proceeding as planned, with all trial sites now active and enrolling participants. HT-001 is designed to treat rash and skin disorders associated with cancer therapy. \n</p>\n<p>\n  \"Hoth's financial position remains robust, with a strong balance sheet that includes over $10 million in cash and no debt,\" the company said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2025 14:44 ET (19:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hoth Therapeutics Shares Recover; Company Has No Plans for Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHoth Therapeutics Shares Recover; Company Has No Plans for Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-09 03:44</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> rebounded after the company said it has no plans for a public or private offering at this time. \n</p>\n<p>\n  Hoth stock was recently up 4.6%, at $2.38, in midday trading Wednesday, after falling sharply to a low point of $1.17 from a 52-week high Tuesday. The stock closed up 178%, to $2.28, on Tuesday, after the company reported favorable interim results from a clinical trial. \n</p>\n<p>\n  The company said it was responding to market rumors and shareholder inquiries. It also said enrollment in a clinical trial of HT-001, its lead drug candidate, is proceeding as planned, with all trial sites now active and enrolling participants. HT-001 is designed to treat rash and skin disorders associated with cancer therapy. \n</p>\n<p>\n  \"Hoth's financial position remains robust, with a strong balance sheet that includes over $10 million in cash and no debt,\" the company said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2025 14:44 ET (19:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1167","symbol_name":"电子制造服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2502029427","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502029427","pubTimestamp":1736365440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Hoth Therapeutics rebounded after the company said it has no plans for a public or private offering at this time.Hoth stock was recently up 4.6%, at $2.38, in midday trading Wednesday, after falling sharply to a low point of $1.17 from a 52-week high Tuesday. The stock closed up 178%, to $2.28, on Tuesday, after the company reported favorable interim results from a clinical trial.The company said it was responding to market rumors and shareholder inquiries. It also said enrollment in a clinical trial of HT-001, its lead drug candidate, is proceeding as planned, with all trial sites now active and enrolling participants. HT-001 is designed to treat rash and skin disorders associated with cancer therapy.\"Hoth's financial position remains robust, with a strong balance sheet that includes over $10 million in cash and no debt,\" the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1167":"电子制造服务","01611":"新火科技控股","BK1612":"加密货币概念","BK4007":"制药","HOTH":"Hoth Therapeutics"},"translate_title":"Hoth Therapeutics股价回升；公司没有发行计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOTH":1,"01611":0.67},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Shares of Hoth Therapeutics rebounded after the company said it has no plans for a public or private offering at this time. \n\n\n  Hoth stock was recently up 4.6%, at $2.38, in midday trading Wednesday, after falling sharply to a low point of $1.17 from a 52-week high Tuesday. The stock closed up 178%, to $2.28, on Tuesday, after the company reported favorable interim results from a clinical trial. \n\n\n  The company said it was responding to market rumors and shareholder inquiries. It also said enrollment in a clinical trial of HT-001, its lead drug candidate, is proceeding as planned, with all trial sites now active and enrolling participants. HT-001 is designed to treat rash and skin disorders associated with cancer therapy. \n\n\n  \"Hoth's financial position remains robust, with a strong balance sheet that includes over $10 million in cash and no debt,\" the company said. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2025 14:44 ET (19:44 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}